Betta Pharmaceuticals300558.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Betta Pharmaceuticals (300558.SZ) trades at a P/E of 38.00x, P/B of 2.69x, P/S of 4.50x, and a dividend yield of 0.35%.
Longitudinal percentile comparison: P/E sits at the 3rd percentile over the trailing 10Y window (vs. 9th percentile over 3Y); P/B sits at the 2nd percentile over the trailing 10Y window (vs. 5th percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 4th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 51st percentile within its industry and the 51st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.35%, ranking at the 71st percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 1.1 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Betta Pharmaceuticals operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 300558 · SZSE: 300558 · 300558
Want the full picture on whether Betta Pharmaceuticals (300558.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 38.00 | ||||||
| P/B (MRQ) | 2.69 | ||||||
| P/S (TTM) | 4.50 | ||||||
| Dividend Yield | 0.35% | ||||||
| Buyback + Div Yield | 0.35% |